Key Takeaways
- A deferred, not lost, season: Revenue fell 12% YoY as a delayed, uneven monsoon pushed crop protection demand out of Q1. Management expects the agriculture cycle to recover, with positive sales growth visible from Q2 itself.
- Premiumization held the margin line: Gross margin expanded 240 bps to 31.6% despite the revenue drop, as premium products rose to 64% of B2C contribution. EBITDA and PAT margins still fell on operating deleverage.
- B2B outperformed while B2C stalled: B2B share jumped from 23% to 34% of revenue on ~10% growth, partly from raw material price spikes and China supply disruption. B2C share fell from 75% to 64%.
- The growth engine is being rebuilt: Two Corteva-collaboration launches, 30+ products in the pipeline, Sotanala and Udhampur capacity coming online, and Kaeros scaling toward a second platform all point to a deliberate multi-year build.
- What to watch next quarter: Whether Q2 actually delivers the promised sales recovery, how fast June's elevated inventory unwinds, and whether the first-half review forces management to walk back its aggressive FY27 growth targets.
Q1 Performance: What Went Wrong
- Revenue decline: Q1 revenue degrew 12% YoY from ₹691 cr to ₹612 cr because channel activity started early in March, then a delayed and uneven monsoon with high temperatures across several regions delayed sowing and crop protection demand.
- Volume vs value: The quarter saw ~13% volume degrowth and ~2% value growth, with B2B growing slightly more than B2C. Management did not split B2B vs B2C volume figures when asked.
- Profitability hit: EBITDA degrew ~20% YoY with margin down from 12.2% to 11.1%, and PAT margin down from 8.4% to 7.2%, reflecting operating deleverage from lower volumes in the slower quarter.
- Patented and combination products slipped: Patented product revenue fell from ₹97 cr to ₹70 cr YoY, mainly on reduced Hachiman sales, while combination products fell from ₹134 cr to ₹98 cr.
- In-licensing and new launches grew: In-licensing revenue rose from ~₹36 cr to ~₹46 cr YoY, products launched last year grew from ₹1.67 cr to ₹2.29 cr, and two new launches this quarter contributed ₹5.50 cr.
- Raw material pressure: Crude and petroleum-linked raw material costs stayed elevated, addressed through calibrated pricing, better product mix, and increasing contribution from differentiated products.
- Inventory elevation: June inventory was slightly elevated due to the slower season start, but management says the big June build is "tumbling down" with substantial improvement expected in Q2 itself.
Aggarwal: "While delayed monsoons impacted the first quarter, we believe the agriculture cycle has largely been deferred rather than lost."
Premiumization & Product Mix
- Gross margin expansion: Gross profit percentage rose from 29% to 31.6% YoY despite the revenue decline, driven by premium product sales rising from 58% to 64% of total B2C contribution.
- Five-year trajectory: Premium product contribution has climbed from 48% five years back to 60%-plus now, with 62% plus last fiscal and 64% this quarter even in a difficult quarter.
- New technology traction: Launches from the last 5-6 years now contribute about one-third of total sales, indicating rising farmer interest in new technology products.
- Premiumization target: Management aims to reach 70% premium product contribution in the next 3-4 years, from 64% achieved this quarter.
- Crop-specific shifts: Reduction seen in cotton and maize crops this year, but other dry crops improving, with increased attraction in oilseeds, pulses, groundnut, and chilli.
- Chilli outlook: Andhra, Telangana and Karnataka should show good increase in chilli crop this year, which management says should be very good for the industry.
B2B, Pricing & Raw Material Dynamics
- B2B growth drivers: Q1 B2B growth of ~10% was driven partly by unexpected price increases in metal, plastic, solvents, emulsifiers and some technicals, plus supply chain disruption from China including container scarcity and freight increases.
- Inventory-gain opacity: Some advantage from high/older inventory contributed to gross profitability, but management called it a "mixed bag" and could not quantify the inventory-gain portion.
- Price hike rollbacks: Management took one hike in March and two in April, attempted one in May but rolled it back because the market was delayed and network sentiment was weak. Rollbacks continued till July, with only strategic cost-linked hikes retained.
- Volatile inputs: Solvents, plastic, HDPE and emulsifiers were highly volatile, with some solvent prices doubling during the quarter.
- Sales returns strategy: Management expects sales returns to reduce to at least half of last year's ₹200 cr because only 1-2 herbicides failed this year and placements were deliberately lower as a strategic call given El Niño announcements from February-March.
Aggarwal: "It was a strategic call what we had taken to place lower, otherwise I could have also achieved the sales number by placing more, but we didn't placed very aggressively this year because we were aware because El Nino announcements were there from the month of February-March, so it was all pre-decided."
New Launches & Partnerships
- Corteva collaborations: GRANUVIA and Spinoace, both launched in collaboration with Corteva Agriscience, were introduced during the quarter through extensive engagement with dealers, distributors, retailers and farmers across the country.
- FY27 launch expectations: Granuvia is expected to touch ~₹20 cr this fiscal, Spinoace is expected to go ₹10 cr+, with combined gross of ₹30-35 cr and ~₹25 cr net possible this fiscal.
- Technology partnerships active: During the quarter, the company continued working with Corteva, Nissan and OAT Agrio to access differentiated technologies and molecules.
- OAT Agrio molecule discovery: Work with OAT Agrio on a new molecule discovery is progressing, helping strengthen the pipeline for coming years.
- New collaborations: Signed 2 new collaborations in the last 1 year, with partner names confidential, developing mixtures including 2-product and 3-product combinations with these and older partners like Nissan.
- Product pipeline: More than 30 products are in the pipeline to be launched in the next 2 years, including mixtures and new AI.
Aggarwal: "At this moment you might be finding our speed little slow, but I can tell you that there are more than 30 products which are in pipeline to be launched in next 2 years. So our pipeline is very, very strong actually for which we are already working."
Capacity Build-Out & Capital Allocation
- Chopanki expansion completed: The company has just completed the Chopanki expansion.
- Dahej status: More than 70% already commercialized, with another 20-30% pending to be commercialized soon. New power connection taken and started, new boiler upcoming, herbicide and insecticide plants divided, with 50-60% equipment utilization on the new plant.
- Dahej potential: At least ₹200 cr addition possible in the technical production plant, with formulation also to support. Detailed numbers for the next 2-3 years to be given next year.
- Sotanala timeline: Formulation facility expected to commence around April-May next year, followed by technical production by Diwali, subject to project schedule. Phase 2 building is being erected now but equipment is not yet installed pending product decisions.
- Sotanala strategy: Going for a fully automatic TCS plant. Some insecticides and fungicides where the company has expertise will be transferred from Chopanki to Sotanala, while Chopanki will handle new AI. 5-6 products identified for first phase, with new AI technicals in second phase.
- Udhampur investment: Invested in Udhampur to differentiate herbicide and insecticide plants, with completion expected within this year.
- Capex normalization: Once current projects are completed, annual capex is expected to normalize around ₹30-40 cr of maintenance capex, allowing focus on utilization, cash generation and returns.
- Energy cost control: On verge of getting solar energy, wind energy and solid fuel advantages by end of Q2 to control power and steam expenses.
- Buyback consideration: Company typically does buyback every 2-3 years, with decision on dividend vs buyback after completing this quarter.
Kaeros & International Business
- Kaeros scaling: More than 40 products already commercialized, with expanding portfolio and distribution footprint while developing B2B and pack-to-pack opportunities.
- Kaeros hiring: ~100 people hired in Q1, with third-party field staff also deployed.
- Kaeros growth target: Target to grow at CAGR of 100% initially, then come down to 50-60%, currently on path of 100% CAGR. Management did not disclose exact revenue figures.
- Kaeros margins: Normalized margin expected around single digit at the moment because expenses are high. Management will not say it will cross double digits until something big is achieved.
- Kaeros portfolio review: Will review product portfolio after Kharif season, may introduce more specialty products given 100 people already on board.
- International momentum: Registrations, partnerships and customer opportunities being developed across Latin America, Europe and ASEAN during the quarter.
- International strategy: Taking calibrated approach to establish relationships before scaling. Technicals sales catching up with good acceptance worldwide, with white labelling plus technicals expected to flourish in international markets.
- CDMO opportunity: Eyeing CDMO business with some partners, in pipeline.
Aggarwal: "The normalized margin also you can believe should be around single digit at the moment. When it goes up then I'll give my comments. I will not say that it will cross double digits now, till I achieve something big."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Sales growth | Positive sales growth for FY27, with positive impact visible from Q2 itself | FY27, visible from Q2 |
| Premiumization | Reach 70% premium product contribution | Next 3-4 years |
| Sotanala formulation | Formulation facility commencement | April-May next year |
| Sotanala technical | Technical production commencement | By Diwali next year, subject to project schedule |
| Udhampur completion | Herbicide and insecticide plant differentiation investment completed | Within this year |
| Capex normalization | Annual capex normalizes to ₹30-40 cr maintenance level | Once current projects complete |
| Sales returns | Reduce to at least half of last year's ₹200 cr | FY27 |
| Granuvia revenue | ~₹20 cr | This fiscal |
| Spinoace revenue | ₹10 cr+ | This fiscal |
| Kaeros growth | 100% CAGR initially, then 50-60% | Medium term |
| Doubling ambition | Double the company | Next 4-5 years |
| Product pipeline | 30+ products launched | Next 2 years |
| Energy cost control | Solar, wind and solid fuel advantages | By end of Q2 |
| Efficiency benefits | AI and advanced technology efficiency benefits | From Q3 onwards (September-October) |
| Dahej addition | At least ₹200 cr addition in technical production | Next 2-3 years, details next year |
| Growth target review | Review after first half before giving revised targets | After H1 FY27 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹612 crores, down 12% YoY from ₹691 crores |
| Gross profit | ₹193.16 crores, down 4% YoY from ₹202 crores |
| Gross margin | 31.6%, up from 29% YoY |
| EBITDA | Down ~20% YoY |
| EBITDA margin | 11.1%, down from 12.2% YoY |
| PAT margin | 7.2%, down from 8.4% YoY |
| Volume degrowth | ~13%, with ~2% value growth from pricing |
| Premium product share of B2C | 64%, up from 58% YoY; target 70% in 3–4 years |
| B2C segment mix | B2C 64%, B2B 34%, export 2%; last year B2C 75%, B2B 23%, export 2% |
| B2C product mix | Insecticide 33%, herbicide 59%, fungicide 5%, PGR 3% |
| Revenue from in-licensing products | ~₹46 crores, up from ~₹36 crores YoY |
| Revenue from patented products | ₹70 crores, down from ₹97 crores YoY, mainly due to lower Hachiman sales |
| Revenue from combination products | ₹98 crores, down from ₹134 crores YoY |
| Sales from newly launched products | ₹5.50 crores from 2 products launched in Q1 |
| Granuvia revenue | ~₹5 crores in Q1; FY27 expectation ~₹20 crores |
| Spinoace revenue | ~₹25 lakhs in Q1; FY27 expectation ₹10 crores plus |
| Kaeros Research products commercialized | More than 40 products |
| Farmer engagement | 3,600+ farmer meetings, 600 field days, 1,400 demonstrations, 15,000+ farmer visits |
| Distribution network | 8,500+ distributors and 70,000 retail network |
| IIL Crop Solutions plots | 36 plots, planning to double across 14 states and 4 crops |
| Sotanala project total investment | ~₹200 crores, with ~₹50 crores for formulations and ~₹150 crores for technical; ~₹70 crores invested so far |
| Dahej new plant utilization | ~50%–60%; potential to add at least ₹200 crores in technical production |
| Normalized annual capex expectation | ₹30–40 crores maintenance capex after current projects complete |